# Tuberculosis Clinical Trials Consortium Study 35

> **NCT03730181** · PHASE1,PHASE2 · COMPLETED · sponsor: **Centers for Disease Control and Prevention** · enrollment: 62 (actual)

## Conditions studied

- Latent Tuberculosis

## Interventions

- **DRUG:** Rifapentine
- **DRUG:** Isoniazid

## Key facts

- **NCT ID:** NCT03730181
- **Lead sponsor:** Centers for Disease Control and Prevention
- **Sponsor class:** FED
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-12
- **Primary completion:** 2024-12-15
- **Final completion:** 2025-05-15
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2026-05-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03730181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03730181, "Tuberculosis Clinical Trials Consortium Study 35". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT03730181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*